CLS is the commercial spin-out of the renowned Coriell Institute for Medical Research, a non-profit biomedical research institution, founded in 1953, dedicated to studying the human genome. In 2007, the Institute launched the Coriell Personalized Medicine Collaborative, a research study seeking to understand the value of personalized medicine and PGx in clinical decision-making and healthcare management. The results of that study led to the founding of Coriell Life Sciences in 2013.
Today, CLS is an international leader in precision medicine, offering the most comprehensive medication safety solution. CLS works with large employers, payers, healthcare systems, and laboratories around the globe, eliminating trial-and-error prescribing, improving population health, and controlling rising healthcare costs. CLS is a trusted provider of genetic laboratory interpretation and reporting services empowering the most precise medical care worldwide.
In recognition of its innovative solutions, CLS has earned top honors as IBM’s Global Entrepreneur of the Year, MedTech Breakthrough’s Best Overall Genomics Company, and a Top Precision Medicine Solution Provider by Healthcare Tech Outlook. In addition to earning a spot on the Inc. 5000, CLS has also received the Employer Health Innovation Roundtable Traction Award and the Pharmacy Benefit Management Institute’s Excellence Award for Cost Containment.
Claimed
